Sign up to save your podcasts
Or
Share Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes
Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC) in the real-world setting. Upon completion of this activity, participants should be better able to: Outline the clinical relevance of real-world evidence in the treatment of HR+/HER2- aBC; Review the latest real-world evidence informing the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- aBC; and Identify patient-centered strategies to integrate real-world evidence into optimized care plans for patients with HR+/HER2- aBC.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC) in the real-world setting. Upon completion of this activity, participants should be better able to: Outline the clinical relevance of real-world evidence in the treatment of HR+/HER2- aBC; Review the latest real-world evidence informing the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- aBC; and Identify patient-centered strategies to integrate real-world evidence into optimized care plans for patients with HR+/HER2- aBC.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
129 Listeners
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
This Week in Cardiology
861 Listeners
JAMA Clinical Reviews
493 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
JAMA Medical News
87 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners